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Abstract
Aim The aim of this study was to assess the impact on the
cost-effectiveness ratio of including measures of produc-
tion and consumption following a health care or health
promotion intervention that improves survival.
Data and methods We defined the net incremental con-
sumption, or future costs, as the change in consumption
minus change in production, while differentiating between
health care and non-health care consumption. Based on
2005 register-based data for the entire Danish population,
we estimated the average value of annual production and
consumption for 1-year age groups. We computed the net
consumption in the remaining expected lifetime and the net
consumption per life year gained for different age groups.
Results Age has a profound effect on the magnitude of net
consumption. When including net incremental consumption
in the cost-effectiveness ratio of a health care or health
promotion intervention, the relative cost-effectiveness
changed up to €21,000 across age groups. The largest dif-
ference in the cost-effectiveness ratio was observed among
the 30-year-olds where costs were reduced significantly due
to significant future net contributions to society.
Conclusion This paper contains cost figures for use in
cost-effectiveness analyses, when the societal perspective
is adopted and future consumption and production effects
are taken into account. The net consumption varies con-
siderably with age. Inclusion of net incremental con-
sumption in the cost-effectiveness analysis will markedly
affect the relative cost-effectiveness of interventions tar-
geted at different age groups. Omitting future cost from
cost-effectiveness analysis may bias the ranking of health
care interventions and favour interventions aimed at older
age groups. We used Danish data for this assessment, and
our results will therefore not represent true figures for other
countries. We do, however, believe that the overall impact
of including net production value in CEA will be similar in
other countries that have similar transfers of income from
the younger age groups to older age groups as well as
publicly financed social and health care services.
Keywords Future costs  Cost-effectiveness analysis 
Life years saved
JEL Classification C31  D61  I10
Background
For more than a decade, the field of economic evaluation in
health care has been accompanied by a discussion about
which cost components to include. Clearly, it is still an
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evolving discipline. The inclusion or exclusion of future
non-medical costs (consumption net of production) is still
being debated.
This topic was first raised in 1996 by the US Panel on
Cost-Effectiveness in Health and Medicine [1], which came
to play a major role by issuing a set of recommendations for
cost-effectiveness analysis. The US Panel defined a refer-
ence case for cost-effectiveness analysis, which excluded
production changes based on the argument that the loss of
utility due to labour market changes when being ill would be
captured by the QALY. Hence, inclusion of the productivity
loss would be double counting. The US Panel also recom-
mended that future unrelated health care costs should be
included if it was found appropriate and feasible. Further, if
unrelated health care costs were included, future non-health
care consumption should also be included. The issue of
future non-medical costs was subsequently addressed from a
welfare theoretic perspective by a number of authors [2–4].
Among them, Meltzer [2] argued that changes in both future
consumption (of non-medical goods) and production should
be included in the cost-effectiveness ratio. However, his
conclusion was challenged by Nyman [5], which launched
another wave of discussion. We base our study on this more
recent discussion on the inclusion of future consumption and
production [5–10].
Our position
We assume a societal perspective of the cost-effectiveness
analysis [11] and suggest that if we are operating in a society
where there are no externalities such as transfer payments, a
CEA based on QALYs that include the value of consumption
(and the value of leisure time) should not include the cost of
consumption, as there are no opportunity costs to other
parties. Nor should the analysis include production gains,
since there is no utility gain beyond the individual’s con-
sumption. However, in the real world, individuals may
increase their consumption without contributing equiva-
lently in terms of production value. Relatives may pay for the
consumption or consumption may be financed via taxes.
Alternatively, individuals may consume less than they earn,
and instead contribute to society (via taxes), to family
members’ education—or to charity. Therefore, we argue that
the figure that should be included in the numerator of the
CUA is the net consumption (consumption minus production
gain), since this figure may represent the opportunity cost to
society if it is positive. If the net consumption is negative, it
constitutes incurred utility beyond what may be captured by
the QALY. If the QALY does not include utility of con-
sumption (but does include the value of leisure time), gross
production gain should figure in the numerator and thus
would reflect the total utility generated.
Whether the QALY does capture utility of own con-
sumption is a contentious issue, however. Lundin and
Ramsberg [8] state that utility from consumption, and
therefore production, is part of the QALY, as it seems
inseparable from utility from health, exemplified by the
utility of being crippled (health), which is very much
related to wheelchair ownership (consumption). Gandjour
[9] argues that Nyman’s suggestion to exclude consump-
tion during added years of life does not apply to con-
sumption costs for the satisfaction of primary needs. He
further states that it is not only the medical treatment that
prolongs life, but also the satisfaction of primary needs
such as food, shelter and clothing. In other words, Gand-
jour argues that resources for primary needs produce utility
captured as additional survival time and hence in the
denominator of the cost-utility ratio. Gandjour thus con-
cludes that according to Nyman’s principle, the costs of
these resources should be included in a CEA. While Lundin
and Ramsberg (2008) and Blomqvist [12] enter into the
discussion of the characteristics of quality-of-life instru-
ments, Gandjour’s argument is more basic and very rele-
vant when we are dealing with evaluation of life-extending
interventions.
Hence, we argue that quality-of-life instruments include
some elements of consumptions utility. At the same time,
we suggest that this issue is of minor importance because
the discussion of whether to include future costs or not is
generally raised in connection with life-extending inter-
ventions. In that case, the relevant argument is the one
presented very convincingly by Gandjour: that living per se
necessarily incurs added future consumption costs, and
therefore the value of life years necessarily includes the
value of consumption (at least to a very significant degree).
Our viewpoint is therefore that since there are consid-
erable transfer payments in most countries, we cannot
assume that consumption and production value cancel each
other out, and these two elements must therefore play a role
in CEA. Further, we believe that there are good arguments
for stating that the utility associated with life extension is
captured by life years or QALYs, and therefore the best
strategy is to avoid double counting of the value of con-
sumption by subtracting the cost of consumption from the
production value in the denominator. This is the theoretical
basis for the empirical research conducted in this study.
Data and methods
The aim of this paper is to assess the empirical effect of
including net future consumption in the cost-effectiveness
computation, and the implications for decision-making
within health care. We thus restrict our focus on the long-
term consequences of health care and health promotion
64 M. Kruse et al.
123
interventions that incur a gain in life expectancy. In par-
ticular when analysing health promotion initiatives, the
impact of keeping people alive for a longer period of time
is salient.
We focus our attention on incremental consumption and
production following a health care intervention and provide
population-based estimates of net incremental consump-
tion. These terms are defined in the box.
Consumption Individual consumption of goods and services
and consumption of health care and other
public goods such as education and social
care
Incremental
consumption
The change in consumption following a health
care intervention, e.g. increased consumption
following a gain in life years
Production Productive income or individual contribution to
society, measured by gross earnings
Incremental
production
The change in production following a health
care intervention, e.g. an increase in
production due to more years in the labour
market
Net incremental
consumption
The difference between incremental
consumption and incremental production,
following a health care intervention. If the net
incremental consumption is positive, the
intervention renders an additional cost, while
if it is negative, it represents a net gain to
society
It seems intuitively clear that net consumption varies
with age, making age a central issue in including net
incremental consumption in the cost-effectiveness analysis.
Only a few authors have assessed the impact of including
net incremental consumption. Meltzer et al. and Manns
et al. [13, 14] analysed specific health care interventions
and concluded that the difference between production and
consumption varies considerably with age.
In addition, a Swedish PhD dissertation computed pro-
duction and consumption by large age intervals, albeit to
some extent based on top-down computations [15]. We
assessed the variation in net incremental consumption
according to age by means of cross-sectional, empirical
data, covering the whole Danish population, on production
and consumption at the individual level, and modelled
these in a lifetime perspective. Our contribution is thus to
estimate the impact of including future net consumption in
a Northern European setting where transfer payments is an
important tool for ensuring welfare. In such countries, one
would expect that there is a significant difference in net
contributions across age groups due to an institutionalised
transfer of benefits across age groups.
Data
In the study, we used 2005 register data at the individual
level for the entire Danish population aged 16 and older.
For each individual, we obtained information on gross
earnings, pension fund payments and taxable income from
the National Income Register. From the Register on Social
Security we obtained information on all social benefits,
including national pensions, early retirement benefit, social
welfare and targeted subsidies. For publicly financed health
care consumption, we derived data from the National
Patient Register for hospital costs and the Health Insurance
Register for primary health care. In addition, we used the
Pharmaceuticals Database for costs of prescription phar-
maceuticals. We merged all data on consumption and
production with the Population Register in order to achieve
information on age and number of household members for
all individuals.
Methods
For each individual, we defined their contribution to pro-
duction as their gross labour market income, including the
share of earnings used for payment into pension funds.
Thus, the production value for a given individual translates
into their own income available for consumption, plus their
saving for consumption in older ages (pension fund pay-
ments), plus their contribution to the utility of others
(family and society via taxes).
Decomposing gross income allows us to estimate how
much income is available for the individuals’ consumption
at a given point in time. Figure 1 displays the information
required to estimate the approximate level of consumption
for each individual. The shaded boxes comprise the mea-
sures that are included in the analysis: production and
consumption.
Children and other individuals without a labour market
income (e.g. individuals living from social welfare bene-
fits) were assumed to have zero production. For individuals
older than pension age (65 years of age), we subtracted an
estimated benefit from private pension funds from pro-
duction, as information on pension benefits could not be
isolated.
Non-health care consumption was estimated by means
of the resources available for non-health care consumption,
i.e. the net disposable income. This includes labour market
income net of taxes and savings, plus public subsidies and
payments from pension funds. We did not have access to
information on taxes paid; therefore, tax payments were
computed using applicable tax rates and rebates and sub-
tracted from taxable income. Note that we are not using
transfer payments as a measure of cost per se, but as an
indicator of the individuals’ ability to consume.
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These figures were aggregated to household level and
divided by the number of household members, assuming that
all household members consume equal amounts. As an
example, the non-health care consumption in a household
consisting of two adults and three children (with no income)
was computed as the sum of disposable income from the two
adults, divided by five. This figure then constituted the non-
health care consumption of each household member. Indi-
vidual non-health care consumption for ages 0–18 was
assumed constant and equal to the average child consump-
tion computed as parent’s non-health care consumption
figures divided by household members.
For consumption of public services other than health
care, e.g. schools and nursing homes, we applied age-
specific figures achieved by means of a top-down assess-
ment of costs of education, day-care, care for the elderly,
public transport etc. Any own payments for public services,
e.g. for child day-care institutions, were included in indi-
vidual non-health care consumption.
For savings, we assumed a constant savings rate of 10
per cent of disposable income during ages 25–60 and
negative savings during ages 18–24 and 67?. This estimate
was based on a survey among Danish pension fund mem-
bers [16] and age-specific savings information from the US
[17]. Consumption of real estate was distributed over the
loan period, as instalments on a loan are included in non-
health care consumption. Revenues from sale of real estate
are not included in our estimate.
Finally, health care consumption was defined as costs of
hospital services, primary health care services and pre-
scription medicine, and was computed at the individual
level. Hospital treatment in Denmark is funded through
taxation and is free of direct charges. Each discharge was
assigned a DRG-tariff, based on the national DRG system
comprising average variable costs per diagnosis group. For
outpatient and emergency contacts, a similar system was
applied [18].
Most contacts in the primary health care sector are free
of charge for the patient. The primary health care sector
comprises general practitioners, practicing specialists,
dentists and physiotherapists. For each contact, a claim is
made to the health authorities based on a set of negotiated
service tariffs. The National Health Insurance register
covers all claims made from practitioners. The tariffs are in
the present context interpreted as the average variable cost
per service.
The Pharmaceuticals Database comprises purchases of
all prescription medicine at an individual level, provided
by primary care pharmacies. The costs of pharmaceuticals
included in health care consumption equals the share of the
price paid by public and private health insurance subsidies.
Out-of-pocket payments (for medication, dentistry and
physiotherapy) were not calculated, but implicitly included
in non-health care consumption as these are goods paid for
out of the monthly budget.
Analysis
The register-based information on production and con-
sumption was derived for all individuals and averaged by
1-year age groups in 2005. This cross-sectional data was
used for describing production and consumption over a
lifetime, thus keeping prices and wages at 2005-level.
We computed the net present value of net consumption
in different ages, both in a lifetime perspective and per life
year saved. Costs and life years were discounted at 3% p.a.
in the base case scenario and at 0 and 5% p.a. in a sensi-
tivity analysis. The lifetime cost figures were computed
with adjustment for survival, using the survival rates for the
Danish population in 2007, and truncated at age 90. Thus,
for the lifetime costs for, e.g. a 40-year-old person, the
costs during ages 40–90 are adjusted for the number of
people surviving to age 90 as well as for the time prefer-
ence for consumption in the future.
Costs per life year gained were computed to enhance
applicability for future cost-effectiveness analysis (CEA).
Often CEA results are displayed as costs per life year gained
(or QALY gained). We therefore computed the net present
value of costs per life year gained. All costs are expressed in
Euros, using the exchange rate €1 = 7.5 DKK.
Results
Figure 2 displays production and consumption (divided
into health care consumption and non-health care con-
sumption) for an average Danish citizen in 2005 by 1 year
age groups.
From age 24 to age 62, production exceeds consump-
tion. This is illustrated by the net consumption (shaded
Productive income
Consumption
Minus savings
Disposable income
Deduction of taxes, consumption of 
others
Gross income
Negative savings
Non-productive income, e.g. 
transfers
Fig. 1 Cost components, individual perspective
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area) being negative. At older ages, consumption is sub-
sidised. The average person aged 24–62 years is a net
contributor, while the average person in the older age
groups is a net beneficiary.
It appears from the figure that consumption of health
care peaks around age 85, while consumption of non-health
care peaks around age 55. Bearing in mind that non-health
care consumption is defined as household income divided
by number of household members, this is not surprising, as
the number of household members usually decreases at this
stage, due to children leaving home, while household
income remains high. Individual non-health care con-
sumption without adjustment for household members peaks
during the 40s.
Table 1 presents the present value of lifetime con-
sumption and production, based on the data in Fig. 2, but
discounted to the time of a given health care or health
promotion intervention. E.g. a health care intervention in a
35-year-old person would render a net present value of
more than a quarter million Euros in a lifetime perspective,
if he or she lives until the age of 90.
When discounting costs and life years at 3% p.a., the
change from net future contributor to net future beneficiary
appears around the age of 50. When future consumption
and production is not discounted (not shown), this change
occurs in the early 40s.
Interventions in older patients incur a positive net con-
sumption as discounted consumption exceeds discounted
production. In particular for old age pensioners with few
earnings, the inclusion of net incremental consumption has
a negative impact on the cost-effectiveness ratio of inter-
ventions targeting these age groups.
In Table 2, the lifetime figures are divided by the
number of remaining life years to obtain the net incre-
mental consumption per added life year. These figures are
applicable in a cost-effectiveness analysis, as they express
the cost per life year gained, and can be used in the
incremental cost-effectiveness ratio (ICER). Life years are
adjusted for survival and discounted by the same discount
factor as net incremental consumption. To illustrate the
impact of the discount factor, results for different discount
rates are presented.
Application of these figures can be illustrated by the
following example of inclusion of net incremental con-
sumption in the cost-effectiveness analysis of a life-saving
health care intervention (e.g. bypass surgery). The surgery
has a (hypothetical) ICER of €15,000 per life year gained
for all age groups compared to medical management, when
net incremental consumption is not included. Inclusion of
net incremental consumption (and applying a discount rate
of 3% p.a.) would produce an ICER of €24,300 per life
year gained for the 65-year-olds, while the cost-effective-
ness of saving the life of a 40-year-old would be as low as
€8,800.
Discussion
In this study, we have illustrated the impact on CEA ratios
of including net incremental consumption, and examined
the magnitude of net consumption for different age groups
in the Danish population. It is obvious that including net
incremental consumption has a major impact on the cost-
effectiveness ratio and that this impact differs between age
groups and between interventions. Thus, inclusion of net
incremental consumption renders a cost difference of
€21,000 between the age group contributing the most and
the age group benefiting the most.
In their 1995 review of costs per life year saved for live
saving interventions, Tengs et al. [19] found that the
median cost per life year saved for any health care inter-
vention was $42,000, equal to about €37,000 using 2005-
prices and exchange rates. Given this level of cost per life
years, a maximum difference of more than €21,000 across
Fig. 2 Production,
consumption and health care
costs, Denmark 2005
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age groups constitutes a significant relative change in cost-
effectiveness ratio estimates.
The illustration of net consumption over a lifetime
shows that health care consumption increases with age.
This is not surprising as the prevalence of most diseases
increase with age. It follows that most health care inter-
ventions target individuals in older ages. On the other hand,
health promotion interventions are not confined to any age
group and could, in fact, be concentrated in younger age
groups. In contrast, we observe that non-health care con-
sumption tends to fall in older ages, which is probably a
joint result of budget constraints as well as physical and
psychological restrictions. In Denmark, the tax level is
relatively high compared to other countries, and authorities
provide substantial subsidies for people outside the labour
market, notably pensioners. In countries where this is not
the case, the drop in consumption around pension age is
likely to be more distinct.
The recognition that inclusion of net consumption in
the cost-effectiveness computation significantly alters the
results of the cost-effectiveness analysis has been made by
other authors [13, 14]. Meltzer et al. [13] analysed the
impact of including net consumption in the analysis of
cost-effectiveness of intensive therapy of young diabetics,
using figures for net consumption that are at level with our
findings. E.g. the net consumption in age group 22–34 was
-$11,069, equal to about -€8,000. Their overall finding was
that for patients with an average age of 22, inclusion of net
consumption decreased the cost-effectiveness ratio from
$22,600 to $9,600 per quality-adjusted life year [13], equal
to a difference of about €9,500. This estimate is very
similar to the results presented in the present paper.
The inclusion of net incremental consumption could
potentially affect the ordering of cost-effectiveness of
interventions, if one intervention is aimed at younger and
the other at older individuals. Also, prioritisation between
health care and health promoting interventions could
change. In the choice between interventions, the balance
between a health-related quality-of-life-improving inter-
vention and a length of life-improving intervention could
change as a consequence of including net incremental
consumption. It is likely that the cost of an intervention that
increases patient’s length of life, changes more markedly as
a result of including future net consumption, than does the
cost of an intervention that primarily improves patient’s
health-related quality of life, because a gain in life years
induces added production and consumption in the added
lifetime. However, an increase in HRQoL could enhance
productivity and thus production. Also, a HRQoL gain
could cause an increase in non-health care consumption,
due to the improved possibility of consuming (travelling,
restaurants etc.) following a health gain. Therefore, a
HRQoL improving intervention also affects future net
Table 1 Discounted production and consumption, EURO
Age at
intervention
Production Non-health
care
consumption
Health care
consumption
Net present
value of net
consumption
0 460,421 517,747 23,021 80,348
5 519,637 520,759 24,330 25,452
10 602,701 518,205 26,067 -58,429
15 699,068 518,551 27,803 -152,714
20 802,028 521,217 31,054 -249,757
25 824,118 493,098 32,720 -298,300
30 801,178 464,148 33,533 -303,497
35 737,655 445,924 34,199 -257,532
40 646,764 433,846 35,372 -177,547
45 535,951 418,417 36,622 -80,912
50 410,263 388,862 37,646 16,246
55 274,646 346,745 38,049 110,148
60 130,242 297,663 37,610 205,032
65 44,092 213,050 35,943 204,901
70 14,358 206,856 32,567 225,065
75 9,053 166,955 27,605 185,506
80 5,828 133,245 21,611 149,027
85 4,235 102,628 15,376 113,769
These figures are not adjusted for survival. The discount rate is 3% p.a
Table 2 Net incremental consumption per gained life year, adjusted
for survival, EURO
Age at
intervention
Expected net
consumption per
added life year,
discounted
at 3% p.a.
Expected net
consumption per
added life year,
discounted
at 5% p.a.
Expected net
consumption per
added life year,
not discounted
0 2,469 5,735 -484
5 789 3,757 -1,233
10 -1,830 310 -2,196
15 -4,840 -3,964 -3,240
20 -8,029 -9,175 -3,597
25 -9,751 -12,234 -3,941
30 -10,118 -13,540 -3,658
35 -8,788 -12,483 -2,604
40 -6,228 -9,675 -966
45 -2,934 -5,777 1,040
50 613 -1,459 3,193
55 4,362 3,214 5,475
60 8,612 8,703 8,034
65 9,258 9,898 8,064
70 11,148 12,134 9,542
75 10,343 11,188 9,003
80 9,725 10,425 8,641
85 9,252 9,777 8,450
The same discount rate was used for costs and life years
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consumption, although the magnitude of this impact is
more uncertain.
The empirical assessment of net incremental consump-
tion was based on very detailed information on every
individual in the Danish population. However, it was
necessary to make a number of assumptions. The figures
on production and information on health care consumption
are retrieved directly from registers, and present as such
quite powerful estimates of true average production and
health care consumption. However, non-health care con-
sumption at individual level had to be estimated based on a
number of assumptions. We assumed certain simplifica-
tions of the tax rates in order to operationalise taxes. We
based our assumptions on cross-sectional data, thus
ignoring cohort effects such as increasing wealth and life
expectancy in younger generations. We also assumed a
constant savings rate during productive ages, that the
revenue from sale of real estate can be ignored, and that all
household members consume to the same extent. Perhaps
the latter assumption is the most problematic. Intra-
household distribution of non-health care consumption
cannot be assessed through registers. Intuitively, it is clear
that consumption of food increases with age, while con-
sumption of other goods, such as clothes, may decrease
with decreasing growth rate. From the figure, it appears
that non-health care consumption during childhood is
rather high, which also relates to the high costs of edu-
cation and day-care institutions.
We tested the assumption of individual non-health care
consumption being equal for all members of a household in
a sensitivity analysis, where we applied the OECD set of
household equivalents [20], according to which a child
equals 0.5 adult (results not shown). Overall, this did not
alter results significantly, aside from a small increase in the
consumption of parents and consequently a small decrease
in the net contribution during productive ages.
Another assumption relates to the computation of pro-
duction gains. This is based on the human capital approach,
according to which, an individual leaving the labour mar-
ket at age 50 incurs a production loss equal to the dis-
counted value of their labour market production for the
remainder of their productive life (about 15 years). The
human capital approach has been criticised as irrelevant in
the presence of unemployment [21]. Instead, these authors
proposed the friction cost approach which was rejected,
however, as not being in accordance with economic theory
[22]. Most importantly, the friction cost approach assumes
that the opportunity cost for another employee to be hired
equals zero.
In addition, in our estimation of production gains, non-
labour market production, such as household production,
was not considered. Hence, the estimated production gains
due to life extension will be underestimated to some extent.
Discounting future costs and effects reflects that indi-
viduals prefer consumption in the present to consumption
in the future. In the analysis, we discounted costs and
effects at 3% p.a. In a sensitivity analyses, we applied
discount rates of 0 and 5%, respectively, reflecting differ-
ent preferences for costs and effects in the future. While it
remains unlikely that individuals’ time preferences do not
change over time [23], albeit differently for costs and
effects, we chose to maintain a fixed discount rate for
simplicity reasons. In a possible application in an economic
evaluation, however, the issue of varying discount rates
should be considered.
The data for the empirical assessment were cross-
sectional, derived for 2005 for all age groups. Therefore,
using the results as lifetime cost figures necessitates the
assumption that no major deviations from 2005 conditions
occur. Notably, the unemployment rate was historically
low in 2005. Higher unemployment rates would render
lifetime production and consumption lower. We assessed
2000 data in order to explore data for a year with higher
unemployment rates, and found a similar pattern albeit
with slightly smaller earnings, adjusted for inflation (results
not shown).
It should also be noted that the analysis does not take
into account any cohort effects. To the extent that pro-
duction and consumption patterns vary considerably across
cohorts, the presented cross-sectional analysis presented
here will be imprecise.
Conclusion
This paper contains cost figures for use in cost-effective-
ness analyses, when the societal perspective is adopted and
future consumption and production effects are taken into
account. We found that age has a profound effect on the
magnitude of net consumption. Inclusion of net incre-
mental consumption incurs a maximum change in the rel-
ative cost-effectiveness of more than €21,000 across age
groups, when costs and effects are discounted with 3% p.a.
The largest difference in the CEA ratio is observed among
the 30-year-olds where the CEA ratio is reduced signifi-
cantly due to significant future net contributions to society.
Inclusion of net incremental consumption in the cost-
effectiveness analysis will affect the relative cost-effec-
tiveness of interventions targeted at different age groups.
Omitting future cost from cost-effectiveness analysis may
bias the ranking of health interventions and favouring
interventions aimed at older age groups. We used Danish
data for this assessment, and our results will therefore not
represent true figures for other countries. We do, however,
believe that the overall impact of including net production
value in CEA will be similar in other countries that have a
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similar transfer of income from the younger age groups to
older groups as well as publicly financed social and health
care services.
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